Pten Null Prostate Epithelium Promotes Localized Myeloid-Derived Suppressor Cell Expansion and Immune Suppression during Tumor Initiation and Progression
暂无分享,去创建一个
L. Tran | P. Nelson | S. Smale | Hong Wu | Lily Wu | S. Priceman | Teresita L. Arenzana | Teresita L Arenzana | M. Ruscetti | Alejandro Garcia | Daniella Bianci-Frias | Elysia Sybert
[1] I. Mellman,et al. Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.
[2] P. Sinha,et al. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. , 2012, Seminars in cancer biology.
[3] D. Gabrilovich,et al. Coordinated regulation of myeloid cells by tumours , 2012, Nature Reviews Immunology.
[4] A. D. De Marzo,et al. Prostate cancer and inflammation: the evidence , 2012, Histopathology.
[5] M. Merad,et al. Studying the mononuclear phagocyte system in the molecular age , 2011, Nature Reviews Immunology.
[6] E. Pamer,et al. Coordinate regulation of tissue macrophage and dendritic cell population dynamics by CSF-1 , 2011, The Journal of experimental medicine.
[7] D. Meyerholz,et al. An inducible model of abacterial prostatitis induces antigen specific inflammatory and proliferative changes in the murine prostate , 2011, The Prostate.
[8] Karin Jirström,et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.
[9] Guangjian Huang,et al. Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function , 2011, Scandinavian journal of gastroenterology.
[10] D. Gabrilovich,et al. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. , 2011, Trends in immunology.
[11] J. D. Di Santo,et al. IL‐1β regulates a novel myeloid‐derived suppressor cell subset that impairs NK cell development and function , 2010, European journal of immunology.
[12] Peter S. Nelson,et al. The Effects of Aging on the Molecular and Cellular Composition of the Prostate Microenvironment , 2010, PloS one.
[13] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[14] Jeffrey W. Pollard,et al. Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.
[15] M. Karin,et al. Immunity, Inflammation, and Cancer , 2010, Cell.
[16] A. Lusis,et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. , 2010, Blood.
[17] Jeffrey Wyckoff,et al. Invasion of human breast cancer cells in vivo requires both paracrine and autocrine loops involving the colony-stimulating factor-1 receptor. , 2009, Cancer research.
[18] P. Schellhammer,et al. Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer , 2009, Cancer.
[19] J. Talmadge,et al. Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells. , 2009, International immunopharmacology.
[20] D. Lopez,et al. The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression. , 2009, Cancer research.
[21] Xuetao Cao,et al. Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF-β11 , 2009, The Journal of Immunology.
[22] J. Talmadge,et al. Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice , 2009, Cancer Immunology, Immunotherapy.
[23] G. Bhagat,et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. , 2008, Cancer cell.
[24] Michelle Collazo,et al. Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice1 , 2008, The Journal of Immunology.
[25] P. Allavena,et al. Cancer-related inflammation , 2008, Nature.
[26] I. Borrello,et al. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. , 2008, Cancer research.
[27] W. Isaacs,et al. Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing , 2008, Clinical Cancer Research.
[28] Mindy I. Davis,et al. A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.
[29] Shunyou Wang,et al. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. , 2007, Cancer research.
[30] J. Fitzpatrick,et al. WHAT IS THE ROLE OF INFLAMMATION IN THE PATHOGENESIS OF PROSTATE CANCER? , 2007, BJU international.
[31] P. Schellhammer,et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] S. Segal,et al. CD11b+/Gr-1+ Immature Myeloid Cells Mediate Suppression of T Cells in Mice Bearing Tumors of IL-1β-Secreting Cells1 , 2005, The Journal of Immunology.
[33] J. Parham,et al. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[34] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[35] E. Stanley,et al. Colony-Stimulating Factor-1 Blockade by Antisense Oligonucleotides and Small Interfering RNAs Suppresses Growth of Human Mammary Tumor Xenografts in Mice , 2004, Cancer Research.
[36] W. Grody,et al. Arginases I and II: do their functions overlap? , 2004, Molecular genetics and metabolism.
[37] P. Nelson,et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. , 2003, Cancer cell.
[38] Bin Yu,et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. , 2003, Cancer research.
[39] M. Colombo,et al. IL-4-Induced Arginase 1 Suppresses Alloreactive T Cells in Tumor-Bearing Mice1 , 2003, The Journal of Immunology.
[40] G. Trinchieri,et al. Reversal of Tumor-induced Dendritic Cell Paralysis by CpG Immunostimulatory Oligonucleotide and Anti–Interleukin 10 Receptor Antibody , 2002, The Journal of experimental medicine.
[41] Andrew V. Nguyen,et al. Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy , 2001, The Journal of experimental medicine.
[42] Alberto Mantovani,et al. Inflammation and cancer: back to Virchow? , 2001, The Lancet.
[43] Nicholas R. English,et al. Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.
[44] Shu-Hsia Chen,et al. Gr-1+ Myeloid Cells Derived from Tumor-Bearing Mice Inhibit Primary T Cell Activation Induced Through CD3/CD28 Costimulation1 , 2000, The Journal of Immunology.
[45] J. Blay,et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. , 1998, Blood.
[46] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .